Comparison of a Human Papillomavirus Test with the Hybrid Capture 2 and a Real-Time PCR Method for 18 High-Risk and Low-Risk Human Papillomavirus Infections in Women

Year : 2025 | Volume : 15 | Issue : 01 | Page : 10 16
    By

    Aaysha Saifi,

  • Sadaf Saifi,

  1. Research Scholar, Department of Microbiology, Monad University Pilakhwa Ghaziabad, Uttar Pradesh, India
  2. Student, Department of Microbiology, Chaudhary Charan Singh University, Meerut, Uttar Pradesh, India

Abstract

Squamous intraepithelial lesions (SILs), which are a kind of cancer, and HUMAN papillomavirus (HPV) viral load have frequently been investigated as a risk factor in findings that were in dispute. These studies made use of several HPV viral quantitation assays [including the commercially available hybrid capture 2 (HC2) assays], which vary in their capacity to consider variations in cervical cell collection, linear dynamic range of viral load quantitation, and identified type-specific compared to cumulative viral load measures. Real-time PCR assays were used to quantify the viral loads of HPV 16 and HPV 18 to see if they differed from HC2 quantity (which does not account for cellularity or multiple infection) in terms of the relationship between viral load and prevalent the SIL and malignancies. In general population, such as the real time PCR measurement of HPV-16, or viral load rose linearly according to the increasing grade of SIL, but the measurement of HPV-18 used equivalent method increased via low grade SIL (LSIL), with high grade SIL experiencing a higher viral load of HPV-18 and malignancies occurring at a rate equivalent to that of cytologically healthy woman. Utilizing the clinical cut point of 1.0 pg/ml, HC2 viral load distinguished between woman with any level of cytological abnormalities (i.e., normal verses >LSIL) and woman who had cytologically normal tissue, but did the alter as the severity of the lesion rose. HC2 did not appear to plateau at large copy number, and there was no indication of considerable variation in the overall cellularity of the specimens. HC2 estimation of the total viral load, however, overstated the total viral load caused by everyone kind of coinfection.

Keywords: Human Papillomavirus (HPV), Hybrid Capture 2 (HC2), Real-Time PCR, High-Risk HPV, Cervical Cancer Detection.

[This article belongs to Research and Reviews: A Journal of Microbiology and Virology ]

How to cite this article:
Aaysha Saifi, Sadaf Saifi. Comparison of a Human Papillomavirus Test with the Hybrid Capture 2 and a Real-Time PCR Method for 18 High-Risk and Low-Risk Human Papillomavirus Infections in Women. Research and Reviews: A Journal of Microbiology and Virology. 2024; 15(01):10-16.
How to cite this URL:
Aaysha Saifi, Sadaf Saifi. Comparison of a Human Papillomavirus Test with the Hybrid Capture 2 and a Real-Time PCR Method for 18 High-Risk and Low-Risk Human Papillomavirus Infections in Women. Research and Reviews: A Journal of Microbiology and Virology. 2024; 15(01):10-16. Available from: https://journals.stmjournals.com/rrjomv/article=2024/view=189242


Browse Figures

References

  1. Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomark Prevent. 2003;12(6):477–4
  2. Gustavsson I, Juko-Pecirep I, Backlund I, Wilander E, Gyllensten U. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. J Clin Virol. 2009;45(2):85–8
  3. Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, Kljukina L, Branovskaja M. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. Journal of Clinical Microbiology. 2004 Jun;42(6):2470–5.
  4. Hooper JE, Hebert JF, Schilling A, Gross ND, Schindler JS, Lagowski JP, Kulesz-Martin M, Corless CL, Morgan TK. Hybrid capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers. Appl Immunohistochem Mol Morphol. 2015;23(4):266–2
  5. Park Y, Lee E, Choi J, Jeong S, Kim HS. Comparison of the Abbott real time high-risk human papillomavirus (HPV), Roche cobas HPV, and hybrid capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol. 2012;50(7):2359–23
  6. Lee JH, Lee NW, Hong SW, Nam YS, Choi JW, Kim YS. Establishment of an efficient multiplex real‐time PCR assay for human papillomavirus genotyping in cervical cytology specimens: comparison with hybrid capture II. Cytopathol. 2011;22(4):261–26
  7. Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C. Comparison of hybrid capture 2 high-risk HPV results in the low positive range with cobas® HPV test results from the ATHENA study. J Clin Virol. 2013;58(1):161–16
  8. Venturoli S, Leo E, Nocera M, Barbieri D, Cricca M, Costa S, Santini D, Zerbini M. Comparison of Abbott real time high risk HPV and hybrid capture 2 for the detection of high-risk HPV DNA in a referral population setting. J Clin Virol. 2012;53(2):121–12
  9. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE, ALTS Group. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J Clin Pathol. 2005;124(5):722–7
  10. Hesselink AT, van den Brule AJ, Brink AA, Berkhof J, Van Kemenade FJ, Verheijen RH, Snijders PJ. Comparison of hybrid capture 2 with in situ hybridization for the detection of high‐risk human papillomavirus in liquid‐based cervical samples. Cancer cytopathology: Interdisciplinary Int J Am Cancer Soc. 2004;102(1):11–18.
Regular Issue Subscription Original Research
Volume 15
Issue 01
Received 24/10/2024
Accepted 13/12/2024
Published 14/12/2024
Publication Time 51 Days
345

Login


My IP

PlumX Metrics